GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2
Сергей Борисович Середенин, Татьяна Александровна Гудашева, Ксения Николаевна Колясникова, Елена Александровна Кузнецова, Татьяна Александровна Воронина, Милада Альнордовна Яркова, Татьяна Алексеевна Антипова, Светлана Александровна Литвинова, Николай Николаевич Золотов · 2018 · RU2646604C2 · patent family 59497169
Published 2018-03-06.
Reported patent results
Narrative findings; numerical extraction incomplete
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Metabolic identity | CPG formation observed during incubation with plasma and brain homogenate | Supports a precursor/metabolite relationship; not a human clinical exposure estimate |
| Cell-injury comparison | Concentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell model | No quantitative cell-survival percentage independently transcribed |
| Animal findings | Increased survival time under experimental hypoxia and anxiolytic-like behavioral findings reported at selected exposures | Different compounds and assays must not be pooled |
These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The claimed class includes phenylacetylglycyl-L-proline ethyl ester, alongside other stereochemical and terminal variants.
The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
- Publication
- RU2646604C2 ↗ · 2018-03-06
- Earliest priority / filing
- 2016-01-12 / 2016-01-12
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 59497169 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Novel glyprolins with nootropic, anti-hypoxic, neuroprotective and anssiylitis activity
Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Ксения Николаевна Колясникова; Елена Александровна Кузнецова; Татьяна Александровна Воронина; Милада Альнордовна Яркова; Татьяна Алексеевна Антипова; Светлана Александровна Литвинова; Николай Николаевич Золотов.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
- These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-59497169. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Борисович Середенин, Татьяна Александровна Гудашева, Ксения Николаевна Колясникова, Елена Александровна Кузнецова, Татьяна Александровна Воронина, Милада Альнордовна Яркова, Татьяна Алексеевна Антипова, Светлана Александровна Литвинова, Николай Николаевич Золотов. GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2 RU2646604C2 · patent family 59497169 2018.
Molekul research summary: https://molekul.io/research/patent-ru2646604c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
CPG & GZK-111
A grouped record for endogenous cyclo(Pro-Gly), its experimental linear precursor GZK-111 and the connection to Noopept metabolism.
Glyprolins & PGP hybrids
A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.